Dr Kas Laboratries Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 14-12-2024
- Paid Up Capital ₹ 0.10 M
as on 14-12-2024
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 12.77%
(FY 2022)
- Profit 88.13%
(FY 2022)
- Ebitda 609.37%
(FY 2022)
- Net Worth -12.33%
(FY 2022)
- Total Assets -19.69%
(FY 2022)
About Dr Kas Laboratries
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mohd Nadeem, Mohd Ahasan, Mohd Faizan, and One other member serve as directors at the Company.
- CIN/LLPIN
U24304UP2016PTC088044
- Company No.
088044
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Dec 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Muzaffarnagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Dr Kas Laboratries Private Limited offer?
Dr Kas Laboratries Private Limited offers a wide range of products and services, including Ayurvedic & Herbal Health Supplement, Herbal Sexual Health Supplement, Wood, Plywood, Veneer & Laminates, Hardwood, Food Storage Boxes & Containers, Thermo Flask, Cooking Spices and Masala, Saffron, Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine.
Who are the key members and board of directors at Dr Kas Laboratries?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohd Nadeem  | Director | 01-Dec-2016 | Current |
| Mohd Ahasan | Director | 01-Dec-2016 | Current |
| Mohd Faizan | Director | 01-Dec-2016 | Current |
| Shan Alam | Director | 01-Dec-2016 | Current |
Financial Performance of Dr Kas Laboratries.
Dr Kas Laboratries Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 12.77% increase. The company also saw a substantial improvement in profitability, with a 88.13% increase in profit. The company's net worth observed a substantial decline by a decrease of 12.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr Kas Laboratries?
In 2018, Dr Kas Laboratries had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dr Kas Laboratries?
Unlock and access historical data on people associated with Dr Kas Laboratries, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr Kas Laboratries, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr Kas Laboratries's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
